Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{175496,
        author = {Ms. Swami Vaishnavi B and Mr. Nilesh N Shinde and Mr. Pathan Ayaj S and Mr. Suryawanshi Vishal V and Ms. Salgar Rupali C and Ms. Jadhav Sneha P and Ms. Surwase Sneha R and Ms. Jadhav Nikita B},
        title = {A Review on Personalized Medicine and Pharmacogenomics},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {11},
        pages = {3151-3156},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=175496},
        abstract = {Personalized medicine is revolutionizing healthcare by tailoring treatments to the unique genetic, environmental, and lifestyle characteristics of each individual. One key component of personalized medicine is pharmacogenomics, which investigates how genetic variations affect an individual’s response to drugs. This paper delves into the convergence of personalized medicine and pharmacogenomics, emphasizing the potential of these fields to enhance therapeutic outcomes, reduce adverse drug reactions, and lower healthcare costs. Additionally, it explores the challenges and opportunities associated with incorporating pharmacogenomics into clinical practice, the ethical considerations involved, and the future direction of personalized healthcare.
Personalized medicine is a versatile field that can be applied in the diagnosis and treatment of various diseases such as cancer, Alzheimer’s, hepatitis, and cardiovascular conditions. It is an emerging area of medical science, offering considerable promise for the future. This review focuses on the characteristics of personalized medicine and its implementation in specific diseases like lung cancer, renal cancer, and rheumatoid arthritis. Furthermore, the paper addresses initiatives taken by the European Union to promote the development of personalized medicine and discusses the challenges encountered during data collection, drug development, and clinical trials. Additionally, the Personalized Medicine Coalitions (PMC) have approved several novel drugs as personalized treatments under the approval of the US FDA.},
        keywords = {Personalized Medicine, Pharmacogenomics, Genetic Variations, Drug Response, Therapeutic Outcomes, Adverse Drug Reactions, Genetic Testing, Precision Medicine.},
        month = {April},
        }